Modified adenoviruses for cancer gene therapy

Area of Science:

• Oncology
• Virology
• Gene Therapy

Background:

• Adenoviral gene therapy is a novel approach for treating resistant cancers.
• Replication-incompetent adenoviruses show limited clinical benefit due to variable coxsackie-adenovirus receptor (CAR) expression on tumor cells.
• CAR deficiency leads to resistance to adenovirus infection, necessitating strategies to improve tumor cell targeting.

Purpose of the Study:

• To review modifications aimed at enhancing the antitumor effects of adenoviral gene therapy.
• To explore strategies for overcoming CAR deficiency and improving adenovirus tropism.
• To discuss the development of selectively oncolytic adenoviruses for improved cancer treatment.

Main Methods:

• Review of current literature on adenoviral gene therapy modifications.
• Analysis of strategies including retargeting complexes and genetic capsid modifications.
• Evaluation of conditionally replicating adenoviruses for targeted tumor cell infection and replication.

Main Results:

• Modifications like retargeting complexes and capsid engineering can circumvent CAR deficiency.
• Selectively oncolytic adenoviruses replicate within tumor cells, causing oncolysis and releasing progeny.
• Normal tissues are spared due to the lack of viral replication in non-tumor cells.

Conclusions:

• Adenoviral gene therapy modifications are crucial for improving antitumor efficacy.
• Overcoming CAR variability and enhancing tumor penetration are key challenges addressed by these modifications.
• Conditionally replicating adenoviruses offer a promising strategy for targeted cancer therapy with reduced systemic toxicity.